We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.11 | 0.25% | 44.10 | 13,405 | 13:45:12 |
From May 2019 to May 2024
By Colin Kellaher
Bristol-Myers Squibb Co. (BMY) said Wednesday the U.S. Food and Drug Administration accepted for priority review its supplemental biologics license application for Opdivo in combination with Yervoy for the treatment of a form of lung cancer.
The New York biopharmaceutical company said the filing covers the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.
Non-small cell lung cancer is one of the most common types of lung cancer, accounting for up to 85% of diagnoses.
Bristol-Myers said the FDA set a target action date of May 15 for the application.
The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period to six months from the standard 10 months.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 15, 2020 07:38 ET (12:38 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
